Dainippon Sumotomo Unit To Offer $190 Million To Buy Elevation Pharma
This article was originally published in PharmAsia News
A Dainippon Sumitomo unit said it would offer up to $190 million to buy Elevation Pharmaceuticals and its nasal allergy aerosol.
You may also be interested in...
Amgen exec calls for more informal agency feedback and alignment between review divisions in understanding design methodologies.
Keeping Track Of Thanksgiving Leftovers: Risdiplam, Artesunate Highlight Glut Of Submissions/Filings
Yes, we know they should be out of the fridge by now, but here are the highlights of submissions and filings during the Thanksgiving week.
HBW Executive Decisions: HELP Endorses Hahn, Industry Award For AHPA's McGuffin, CHPA, Herbalife Hires
CHPA adds Allgaier to head development, relations; Vetere joins Herbalife as VP, CIO; Hahn's FDA commissioner nomination clears HELP committee; and AHPA's McGuffin recognized as 2019 Industry Leader.